数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Remi Barbier President, Chief Executive Officer, Chairman of the Board and Director 60 107.32万美元 未持股 2020-03-17
Nadav Friedmann Chief Medical and Operating Officer and Director 77 41.70万美元 未持股 2020-03-17
Robert Z. Gussin Director 82 6.67万美元 未持股 2020-03-17
Patrick J. Scannon Director 72 3.34万美元 未持股 2020-03-17
Michael J. O’donnell Director 61 3.34万美元 未持股 2020-03-17
Sanford R. Robertson Director 88 6.67万美元 未持股 2020-03-17
Saira Ramasastry Director 44 5.01万美元 未持股 2020-03-17

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Remi Barbier President, Chief Executive Officer, Chairman of the Board and Director 60 107.32万美元 未持股 2020-03-17
Nadav Friedmann Chief Medical and Operating Officer and Director 77 41.70万美元 未持股 2020-03-17
Eric J. Schoen Chief Financial Officer 51 25.14万美元 未持股 2020-03-17

董事简历

中英对照 |  中文 |  英文
Remi Barbier

Remi Barbier,本公司的创始人;自本公司1998年成立之时起,担任总裁、首席执行官、董事长。此前,他参与了以下公司的成立或成长:Exelixis Inc.,功能基因组学公司;ArQule, Inc.,化学公司;EnzyMed, Inc.,现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月,他担任Exelixis的首席运营官。1993-1995,他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。


Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.
Remi Barbier,本公司的创始人;自本公司1998年成立之时起,担任总裁、首席执行官、董事长。此前,他参与了以下公司的成立或成长:Exelixis Inc.,功能基因组学公司;ArQule, Inc.,化学公司;EnzyMed, Inc.,现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月,他担任Exelixis的首席运营官。1993-1995,他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。
Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.
Nadav Friedmann

Nadav Friedmann,1998年起担任董事。他从2001年10月起,担任首席运营官;2004年起,担任首席医学与运营官。他是EMET Research的所有者、总裁,这是一家制药行业的咨询公司。1997-2000,他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官;1995-1997,他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995,他担任Xoma Ltd.(原Xoma Corporation)的临床研究副总裁。1980-1991,他在Johnson & Johnson (J&J)担任过各种领导职务,包括副总裁、J&J生物技术中心研究总监。此前,他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。


Nadav Friedmann has served as a director since September 1998. Dr. Friedmann has served as Chief Operating Officer since 2001 and Chief Medical and Operating Officer since 2004. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.
Nadav Friedmann,1998年起担任董事。他从2001年10月起,担任首席运营官;2004年起,担任首席医学与运营官。他是EMET Research的所有者、总裁,这是一家制药行业的咨询公司。1997-2000,他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官;1995-1997,他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995,他担任Xoma Ltd.(原Xoma Corporation)的临床研究副总裁。1980-1991,他在Johnson & Johnson (J&J)担任过各种领导职务,包括副总裁、J&J生物技术中心研究总监。此前,他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。
Nadav Friedmann has served as a director since September 1998. Dr. Friedmann has served as Chief Operating Officer since 2001 and Chief Medical and Operating Officer since 2004. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.
Robert Z. Gussin

Robert Z. Gussin,2003年3月起担任董事。他在J&J 工作了26年,最后的职务是首席科学官、企业科学与技术副总裁,任期从1986年直到2000年退休。担任该职之前,他在J&J 的McNeil部门工作了12年,最后的职务是研发副总裁、科学事务副总裁。1967-1974,他在制药公司Lederle Laboratories担任过各种研究性的职务。他目前担任Duquesne University的董事、Duquesne University Pharmacy School咨询委员会成员、University of Michigan Medical School Department of Pharmacology的咨询委员会成员。他以优异成绩在Duquesne University获得了学士学位、硕士学位、博士学位,并在University of Michigan, Ann Arbor获得药理学博士学位。


Robert Z. Gussin has served as a director since March 2003. Dr. Gussin worked at Johnson & Johnson for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.
Robert Z. Gussin,2003年3月起担任董事。他在J&J 工作了26年,最后的职务是首席科学官、企业科学与技术副总裁,任期从1986年直到2000年退休。担任该职之前,他在J&J 的McNeil部门工作了12年,最后的职务是研发副总裁、科学事务副总裁。1967-1974,他在制药公司Lederle Laboratories担任过各种研究性的职务。他目前担任Duquesne University的董事、Duquesne University Pharmacy School咨询委员会成员、University of Michigan Medical School Department of Pharmacology的咨询委员会成员。他以优异成绩在Duquesne University获得了学士学位、硕士学位、博士学位,并在University of Michigan, Ann Arbor获得药理学博士学位。
Robert Z. Gussin has served as a director since March 2003. Dr. Gussin worked at Johnson & Johnson for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.
Patrick J. Scannon

Patrick J. Scannon,2007年起担任董事。他是XOMA的创始人之一,现任其董事。他从2006年起,担任XOMA的执行副总裁、首席生物技术官。1993-2006,他担任XOMA的首席科学与医学官。他获得了University of California, Berkeley的有机化学博士学位、Medical College of Georgia的医学博士学位。


Patrick J. Scannon has served as a director since December 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016 Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006 Dr. Scannon served as Chief Scientific and Medical Officer of XOMA. Dr. Scannon retired from XOMA and resigned from XOMA’s board of directors in 2016. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.
Patrick J. Scannon,2007年起担任董事。他是XOMA的创始人之一,现任其董事。他从2006年起,担任XOMA的执行副总裁、首席生物技术官。1993-2006,他担任XOMA的首席科学与医学官。他获得了University of California, Berkeley的有机化学博士学位、Medical College of Georgia的医学博士学位。
Patrick J. Scannon has served as a director since December 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016 Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006 Dr. Scannon served as Chief Scientific and Medical Officer of XOMA. Dr. Scannon retired from XOMA and resigned from XOMA’s board of directors in 2016. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.
Michael J. O’donnell

Michael J. O’donnell,1998年起担任董事。他从2011年1月起,担任律师事务所Morrison & Foerster, LLP的合伙人。1993年至2011年1月,他是律师事务所Wilson Sonsini Goodrich & Rosati, Professional Corporation的合伙人。orrison & Foerster, LLP是本公司的企业法律顾问,为本公司提供法律咨询服务。目前,他是许多上市及私营的生物制药与生命科学公司的企业法律顾问。他以优异的成绩获得Harvard University的法律博士学位,并以优等生的荣誉获得Bucknell University的学士学位。


Michael J. O’Donnell, Esq. has served as a director since 1998. Mr. O’Donnell has been a member of the law firm of Morrison & Foerster, LLP since January 2011. From 1993 to January 2011 Mr. O’Donnell was a member of the law firm of Wilson Sonsini Goodrich & Rosati, Professional Corporation. Morrison & Foerster, LLP is the Company’s corporate counsel and provides legal services to the Company. Mr. O’Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Mr. O’Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.
Michael J. O’donnell,1998年起担任董事。他从2011年1月起,担任律师事务所Morrison & Foerster, LLP的合伙人。1993年至2011年1月,他是律师事务所Wilson Sonsini Goodrich & Rosati, Professional Corporation的合伙人。orrison & Foerster, LLP是本公司的企业法律顾问,为本公司提供法律咨询服务。目前,他是许多上市及私营的生物制药与生命科学公司的企业法律顾问。他以优异的成绩获得Harvard University的法律博士学位,并以优等生的荣誉获得Bucknell University的学士学位。
Michael J. O’Donnell, Esq. has served as a director since 1998. Mr. O’Donnell has been a member of the law firm of Morrison & Foerster, LLP since January 2011. From 1993 to January 2011 Mr. O’Donnell was a member of the law firm of Wilson Sonsini Goodrich & Rosati, Professional Corporation. Morrison & Foerster, LLP is the Company’s corporate counsel and provides legal services to the Company. Mr. O’Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Mr. O’Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.
Sanford R. Robertson

Sanford R. Robertson,2003年10月担任董事长一职。他是范斯高合伙企业(技术收购基金公司)的首要合伙人。在创立公司之前,2000年1月,他是罗伯森和史蒂芬公司(一家技术投资公司)的创立者和主席。他已经在对家技术公司担任过技术投资人和咨询顾问,他还是罗伯特、科尔曼、希柏和维塞尔公司(后来重命名为蒙哥马利证券公司)的创立者。目前,他人三家上市公司(杜比研究所、疼痛治疗公司和PRX公司)的董事长。在过去五年里,他还是嘉信慈善基金董事长,拥有密歇根大学的工商管理学士和硕士学位。


Sanford R. Robertson has served as a director since September 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank sold to BankBoston in 1998. Mr. Robertson is the committees lead director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications. Mr. Robertson received his B.A. and M.B.A. degrees with distinction from the University of Michigan.
Sanford R. Robertson,2003年10月担任董事长一职。他是范斯高合伙企业(技术收购基金公司)的首要合伙人。在创立公司之前,2000年1月,他是罗伯森和史蒂芬公司(一家技术投资公司)的创立者和主席。他已经在对家技术公司担任过技术投资人和咨询顾问,他还是罗伯特、科尔曼、希柏和维塞尔公司(后来重命名为蒙哥马利证券公司)的创立者。目前,他人三家上市公司(杜比研究所、疼痛治疗公司和PRX公司)的董事长。在过去五年里,他还是嘉信慈善基金董事长,拥有密歇根大学的工商管理学士和硕士学位。
Sanford R. Robertson has served as a director since September 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank sold to BankBoston in 1998. Mr. Robertson is the committees lead director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications. Mr. Robertson received his B.A. and M.B.A. degrees with distinction from the University of Michigan.
Saira Ramasastry

Saira Ramasastry,2013年2月起担任董事。2013年之前,她是本公司的顾问。她从2009年起,担任Life Sciences Advisory, LLC的管理合伙人,这是一个生命科学行业的咨询公司。1999-2009,她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998,她是投资银行公司Wasserstein Perella & Co.并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事,是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员,也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位,并在 University of Cambridge获得管理研究的学术硕士学位。


Saira Ramasastry has served as a director since February 2013. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Therapeutics, Inc., VIR Biotechnology, Inc., Innovate Biopharmaceuticals, Inc. and Glenmark Pharmaceuticals Ltd., each a publicly-held biopharmaceutical company, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the head of business and sustainability for the European Prevention of Alzheimer’s Dementia EPAD. She received her B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as an M. Phil. in Management Studies from the University of Cambridge.
Saira Ramasastry,2013年2月起担任董事。2013年之前,她是本公司的顾问。她从2009年起,担任Life Sciences Advisory, LLC的管理合伙人,这是一个生命科学行业的咨询公司。1999-2009,她是投资银行公司Merrill Lynch & Company的投资银行家。1997-1998,她是投资银行公司Wasserstein Perella & Co.并购部门的金融分析师。她目前是两家上市制药公司Sangamo Biosciences 和 Repros Therapeutics的董事,是Michael J. Fox Foundation for Parkinson’s Research行业咨询委员会成员,也是American Liver Foundation的董事。她以优等生的成绩获得了Stanford University的经济学士学位、管理学与工程硕士学位,并在 University of Cambridge获得管理研究的学术硕士学位。
Saira Ramasastry has served as a director since February 2013. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009 Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Therapeutics, Inc., VIR Biotechnology, Inc., Innovate Biopharmaceuticals, Inc. and Glenmark Pharmaceuticals Ltd., each a publicly-held biopharmaceutical company, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the head of business and sustainability for the European Prevention of Alzheimer’s Dementia EPAD. She received her B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as an M. Phil. in Management Studies from the University of Cambridge.

高管简历

中英对照 |  中文 |  英文
Remi Barbier

Remi Barbier,本公司的创始人;自本公司1998年成立之时起,担任总裁、首席执行官、董事长。此前,他参与了以下公司的成立或成长:Exelixis Inc.,功能基因组学公司;ArQule, Inc.,化学公司;EnzyMed, Inc.,现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月,他担任Exelixis的首席运营官。1993-1995,他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。


Remi Barbier,本公司的创始人;自本公司1998年成立之时起,担任总裁、首席执行官、董事长。此前,他参与了以下公司的成立或成长:Exelixis Inc.,功能基因组学公司;ArQule, Inc.,化学公司;EnzyMed, Inc.,现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月,他担任Exelixis的首席运营官。1993-1995,他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。
Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.
Nadav Friedmann

Nadav Friedmann,1998年起担任董事。他从2001年10月起,担任首席运营官;2004年起,担任首席医学与运营官。他是EMET Research的所有者、总裁,这是一家制药行业的咨询公司。1997-2000,他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官;1995-1997,他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995,他担任Xoma Ltd.(原Xoma Corporation)的临床研究副总裁。1980-1991,他在Johnson & Johnson (J&J)担任过各种领导职务,包括副总裁、J&J生物技术中心研究总监。此前,他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。


Nadav Friedmann,1998年起担任董事。他从2001年10月起,担任首席运营官;2004年起,担任首席医学与运营官。他是EMET Research的所有者、总裁,这是一家制药行业的咨询公司。1997-2000,他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官;1995-1997,他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995,他担任Xoma Ltd.(原Xoma Corporation)的临床研究副总裁。1980-1991,他在Johnson & Johnson (J&J)担任过各种领导职务,包括副总裁、J&J生物技术中心研究总监。此前,他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。
Nadav Friedmann has served as a director since September 1998. Dr. Friedmann has served as Chief Operating Officer since 2001 and Chief Medical and Operating Officer since 2004. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.
Eric J. Schoen

Eric J. Schoen,他于2010年7月加入公司,担任我们公司的总会计师。他于2013年5月28日被任命为财务副总裁,并一直担任我们的首席会计官(2011年10月以来)。加入公司之前,他曾担任Borland Software公司(一个公开上市的软件开发公司)的收入总会计师(从2007年到2010年)。从2000年到2007年,他担任Trilogy Enterprises公司、Momentum Software公司和Alticast公司的公司总会计师和财务董事。他也曾任职普华永道(PricewaterhouseCoopers)9年,最近担任审计及咨询、交易服务和全球资本市场实践经理。他获得了Santa Clara University的金融学士学位。


Eric J. Schoen,他于2010年7月加入公司,担任我们公司的总会计师。他于2013年5月28日被任命为财务副总裁,并一直担任我们的首席会计官(2011年10月以来)。加入公司之前,他曾担任Borland Software公司(一个公开上市的软件开发公司)的收入总会计师(从2007年到2010年)。从2000年到2007年,他担任Trilogy Enterprises公司、Momentum Software公司和Alticast公司的公司总会计师和财务董事。他也曾任职普华永道(PricewaterhouseCoopers)9年,最近担任审计及咨询、交易服务和全球资本市场实践经理。他获得了Santa Clara University的金融学士学位。
Eric J. Schoen has served as Chief Financial Officer since October 2018. Prior to joining the Company, Mr. Schoen served in numerous financial leadership roles. Most recently, he served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Vermillion, Inc., a publicly-held bioanalytical-based women’s health company focused on gynecologic disease, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his B.S. in Finance from Santa Clara University.